Berlin - Delayed Quote EUR

Cassava Sciences Inc (PX91.BE)

Compare
2.7360
+0.0260
+(0.96%)
At close: January 10 at 8:08:17 AM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
134,748.0000
105,957.0000
80,020.0000
32,868.0000
6,792.0000
Operating Income
-134,748.0000
-105,957.0000
-80,020.0000
-32,868.0000
-6,792.0000
Net Non Operating Interest Income Expense
8,289.0000
7,833.0000
2,777.0000
49.0000
112.0000
Other Income Expense
108,795.0000
907.0000
997.0000
434.0000
346.0000
Pretax Income
-17,664.0000
-97,217.0000
-76,246.0000
-32,385.0000
-6,334.0000
Net Income Common Stockholders
-17,664.0000
-97,217.0000
-76,246.0000
-32,385.0000
-6,334.0000
Diluted NI Available to Com Stockholders
-61,457.0000
-97,217.0000
-76,246.0000
-32,385.0000
-6,334.0000
Basic EPS
-0.43
-2.32
-1.90
-0.82
-0.24
Diluted EPS
-1.38
-2.32
-1.90
-0.82
-0.24
Basic Average Shares
44,848.7500
41,932.0000
40,202.0000
39,405.0000
26,105.0000
Diluted Average Shares
45,124.0000
41,932.0000
40,202.0000
39,405.0000
26,105.0000
Total Operating Income as Reported
-134,748.0000
-105,957.0000
-80,020.0000
-32,868.0000
-6,446.0000
Total Expenses
134,748.0000
105,957.0000
80,020.0000
32,868.0000
6,792.0000
Net Income from Continuing & Discontinued Operation
-17,664.0000
-97,217.0000
-76,246.0000
-32,385.0000
-6,334.0000
Normalized Income
-125,847.0000
-97,217.0000
-76,246.0000
-32,385.0000
-6,680.0000
Interest Income
8,289.0000
7,833.0000
2,777.0000
49.0000
112.0000
Net Interest Income
8,289.0000
7,833.0000
2,777.0000
49.0000
112.0000
EBIT
-134,748.0000
-105,957.0000
-80,020.0000
-32,868.0000
-6,792.0000
EBITDA
-133,520.0000
-104,427.0000
-78,719.0000
-32,334.0000
-6,770.0000
Reconciled Depreciation
1,228.0000
1,530.0000
1,301.0000
534.0000
22.0000
Net Income from Continuing Operation Net Minority Interest
-17,664.0000
-97,217.0000
-76,246.0000
-32,385.0000
-6,334.0000
Total Unusual Items Excluding Goodwill
108,183.0000
--
--
--
346.0000
Total Unusual Items
108,183.0000
--
--
--
346.0000
Normalized EBITDA
-241,703.0000
-104,427.0000
-78,719.0000
-32,334.0000
-7,116.0000
12/31/2020 - 7/19/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BX2.DU BioXcel Therapeutics Inc
0.3558
-2.87%
 
BX2.F BioXcel Therapeutics, Inc.
0.3673
+0.27%
 
ZVAA.F Cellectis S.A.
1.7100
-7.57%
 
BX2.MU BioXcel Therapeutics Inc
0.3604
-5.16%
 
XRTX.V XORTX Therapeutics Inc.
1.8500
-5.13%
 
NVV1.F Novavax, Inc.
8.89
-6.92%